Marker Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Marker Therapeutics's earnings are forecast to decline at 33.3% per annum while its annual revenue is expected to grow at 81% per year. EPS is expected to grow by 4.3% per annum.
Anahtar bilgiler
-33.3%
Kazanç büyüme oranı
4.3%
EPS büyüme oranı
Biotechs kazanç büyümesi | 27.1% |
Gelir büyüme oranı | 81.0% |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | Low |
Son güncelleme | 21 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Oct 04Marker Therapeutics awarded $2M FDA grant for leukemia candidate
Sep 13Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M
Aug 11Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky
Jun 17Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely
Mar 04Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Nov 19Marker Therapeutics: Passing Through A Catalyst Desert
Oct 22Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
Aug 17Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation
May 04Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Feb 22Marker shares rise as it completes construction of its cGMP manufacturing facility
Jan 13FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy
Jan 05Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?
Dec 29Marker Therapeutics EPS misses by $0.02
Nov 09Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | N/A | -44 | N/A | N/A | 1 |
12/31/2025 | N/A | -35 | N/A | N/A | 1 |
12/31/2024 | 4 | -15 | N/A | N/A | 1 |
6/30/2024 | 4 | -10 | -11 | -11 | N/A |
3/31/2024 | 3 | -12 | -14 | -14 | N/A |
12/31/2023 | 3 | -14 | -16 | -16 | N/A |
9/30/2023 | 3 | -14 | -20 | -20 | N/A |
6/30/2023 | 4 | -17 | -27 | -27 | N/A |
3/31/2023 | 4 | -14 | -18 | -21 | N/A |
12/31/2022 | 4 | -20 | -27 | -27 | N/A |
9/30/2022 | 4 | -26 | -26 | -26 | N/A |
6/30/2022 | 3 | -33 | -27 | -25 | N/A |
3/31/2022 | 2 | -43 | -36 | -31 | N/A |
12/31/2021 | 1 | -42 | -30 | -27 | N/A |
9/30/2021 | N/A | -41 | -35 | -28 | N/A |
6/30/2021 | N/A | -36 | -34 | -27 | N/A |
3/31/2021 | 0 | -31 | -35 | -24 | N/A |
12/31/2020 | 0 | -29 | -29 | -20 | N/A |
9/30/2020 | 1 | -25 | -24 | -19 | N/A |
6/30/2020 | 1 | -23 | -23 | -19 | N/A |
3/31/2020 | 0 | -23 | -19 | -19 | N/A |
12/31/2019 | 0 | -21 | -19 | -18 | N/A |
9/30/2019 | N/A | -152 | -20 | -20 | N/A |
6/30/2019 | N/A | -151 | -18 | -18 | N/A |
3/31/2019 | 0 | -150 | -16 | -16 | N/A |
12/31/2018 | 0 | -148 | -15 | -14 | N/A |
9/30/2018 | 0 | -15 | -11 | -11 | N/A |
6/30/2018 | 0 | -15 | -9 | -9 | N/A |
3/31/2018 | 0 | -12 | N/A | -9 | N/A |
12/31/2017 | 0 | -11 | N/A | -8 | N/A |
9/30/2017 | 0 | -10 | N/A | -8 | N/A |
6/30/2017 | N/A | -8 | N/A | -8 | N/A |
3/31/2017 | N/A | 0 | N/A | -8 | N/A |
12/31/2016 | N/A | -2 | N/A | -7 | N/A |
9/30/2016 | N/A | -3 | N/A | -6 | N/A |
6/30/2016 | N/A | 28 | N/A | -5 | N/A |
3/31/2016 | N/A | -38 | N/A | -4 | N/A |
12/31/2015 | N/A | -34 | N/A | -4 | N/A |
9/30/2015 | N/A | -33 | N/A | -4 | N/A |
6/30/2015 | N/A | -63 | N/A | -3 | N/A |
3/31/2015 | N/A | -2 | N/A | -3 | N/A |
12/31/2014 | N/A | -31 | N/A | -2 | N/A |
9/30/2014 | N/A | -34 | N/A | -1 | N/A |
6/30/2014 | N/A | -33 | N/A | -1 | N/A |
3/31/2014 | N/A | -35 | N/A | -1 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: MRKR is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: MRKR is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: MRKR is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: MRKR's revenue (81% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: MRKR's revenue (81% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if MRKR's Return on Equity is forecast to be high in 3 years time